Atopic Dermatitis / Atopic Eczema | Disease Landscape & Forecast | G7 | 2023
Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of AD treatment are to protect the skin barrier, reduce inflammation, and alleviate itch. Topical therapies are often effective for mild disease but have suboptimal safety, tolerability, and compliance. More-effective therapies for topical-refractory patients and, more generally, moderate to severe AD patients are a key focus of the drug development that is now driving the AD market. This upheaval began with the 2017 launches of Sanofi / Regeneron’s injectable biologic Dupixent (dupilumab) and Pfizer’s nonsteroidal topical cream Eucrisa (crisaborole). Since then, eight agents have been approved: three oral JAK inhibitors (Eli Lilly’s Olumiant [baricitinib], AbbVie’s Rinvoq [upadacitinib], and Pfizer’s Cibinqo [abrocitinib]); three nonsteroidal topical agents (Japan Tobacco’s Corectim [delgocitinib], Incyte’s Opzelura [ruxolitinib], and Otsuka / Acrotech Biopharma’s Moizerto [difamilast]); one IL-31 inhibitor (Galderma / Chugai / Maruho’s Mitchga [nemolizumab]); and Leo Pharma’s targeted biologic Adbry / Adtralza (tralokinumab). This report provides a comprehensive analysis of AD patient populations, current disease management, unmet needs, and the potential of current and emerging drugs.
Questions answered
- What are the mild, moderate, and severe AD subpopulation sizes; how will they change by 2032? How well are they served by current AD therapies?
- How have Dupixent and Eucrisa been incorporated into the AD treatment algorithm? What market niches are newly launched oral JAK inhibitors (e.g., Cibinqo, Rinvoq, Olumiant), topicals (e.g., Corectim, Opzelura, Moizerto), and other biologics (e.g., Adbry, Mitchga) beginning to occupy?
- What therapies are in development for AD? Of these therapies, which are best poised to achieve commercial success?
- What are the greatest unmet needs in the treatment of AD, and to what degree will therapies in the pipeline address these needs?
Content highlights
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan
Primary research: 17 country-specific interviews with thought leaders; supported by survey data collected for this and other Clarivate research
Epidemiology: Diagnosed and drug-treated prevalence of AD by country, 12-month total and diagnosed prevalence of AD by severity
Emerging therapies: Phase 3 / PR / approved: 15 drugs; Phase 1/2: 20+ drugs; coverage of select early-phase products
Forecast: 10-year, annualized, drug-level sales and patient share of key AD therapies through 2032, segmented by brands / generics, disease severity, and pediatric / adult subpopulations
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
